Novo Nordisk A/S
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Novo Nordisk A/S, a leading global healthcare company founded in 1923 and headquartered in Bagsværd, Denmark, develops, manufactures and markets pharmaceutical products and services focused on diabetes care, obesity management, rare blood disorders, growth hormone therapy and hormone replacement therapy; its core offerings include GLP-1 receptor agonists such as semaglutide branded as Ozempic and Rybelsus for type 2 diabetes and Wegovy for obesity, insulins including rapid-acting NovoLog/NovoRapid, long-acting Tresiba and Levemir, and human insulins like Novolin R, alongside hemostasis products such as NovoSeven and NovoEight for hemophilia, and growth hormone therapies; the company operates production facilities in nine countries, employs over 76,000 people and markets its products in approximately 170 countries worldwide, with majority control held by Novo Holdings A/S, a wholly owned entity of the Novo Nordisk Foundation. Recent strategic developments include the October 2025 acquisition of Akero Therapeutics for up to $5.2 billion to bolster its metabolic dysfunction-associated steatohepatitis (MASH) pipeline, a May 2025 partnership and licensing agreement with Septerna potentially worth $2.2 billion for oral small molecule therapies targeting obesity, type 2 diabetes and cardiometabolic disorders, a December 2024 collaboration with Photys Therapeutics for up to $186 million in proximity-based therapeutics for cardiometabolic targets, filing for FDA approval of a higher 7.2 mg dose of Wegovy injection in November 2025, positive phase 2 results for amycretin showing significant weight loss and HbA1c reduction in type 2 diabetes patients in November 2025, and workforce reduction of 9,000 positions or about 9% globally in September 2025 amid competitive pressures from generic entrants; the company continues expanding manufacturing capacity, including a $4.1 billion semaglutide plant in Clayton, North Carolina announced in June 2024 and acquisition of Catalent sites, while appointing Maziar Mike Doustdar as CEO effective August 2025.
The Next Phase Of The Obesity Drug Race
Drugmakers race to find a place in the next wave of obesity drugs
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
Novo Nordisk (NVO) Outpaces Stock Market Gains: What You Should Know
Eli Lilly vs Novo Nordisk: The Battle for Obesity Drug Supremacy
Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet
Novo Nordisk hit by cyber incident, probes data breach
Novo Nordisk's Wegovy Weight Loss Pill Approved in the U.K.
Why Pfizer Stock Popped Today
Novo Nordisk A/S: IT Security incident at Novo Nordisk
Employers Rethink GLP-1 Coverage
Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK
The GLP-1 stock nobody is pricing in isn't a drugmaker
Healthcare ETFs: From Broad Exposure to Big Breakthroughs
Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Novo Nordisk faces off in court with South African weight-loss drug compounder
Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before
Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy